Loeser Andreas, Vergho Daniel C, Katzenberger Tiemo, Brix David, Kocot Arkadius, Spahn Martin, Gerharz Elmar W, Riedmiller Hubertus
Department of Urology, Institute of Pathology, Julius-Maximilians-University Medical School, Würzburg, Germany.
Urology. 2009 Aug;74(2):370-2. doi: 10.1016/j.urology.2009.03.014.
To compare retrospectively the outcome of testis-sparing surgery (TSS) to radical orchiectomy (RO) in patients with Leydig cell tumor (LCT).
Between 1992 and 2008, 16 patients with LCT of the testis were identified. All but 1 tumor could be detected by ultrasonography. Alpha-fetoprotein and beta-human chorionic gonadotropin levels were normal in all patients. Eight patients underwent RO (mean age at surgery 42 years [27-61]; median tumor size 12.9 mm [10-25]) and the remaining 8 underwent TSS (mean age at surgery 34 years [18-49]; median tumor size 8.6 mm [4-23]). Staging (abdominal computed tomography and chest x-ray or thoracic computed tomography) was negative in all patients.
Median follow-up was 77 months (17-186) after RO and 42 months (1-86 months) after TSS. There was no local recurrence or metastasis in patients after RO. A metachronous LCT was removed from the spermatic cord 29 months after TSS of the ipsilateral testis in 1 patient. Another patient underwent surgical exploration of the testis 31 months after ipsilateral TSS because of a suspicious lesion identified in ultrasonography; a tumor was ruled out by histopathology.
In the medium term, TSS is a safe procedure in patients with LCT <25 mm.
回顾性比较睾丸支持细胞肿瘤(LCT)患者行保留睾丸手术(TSS)与根治性睾丸切除术(RO)的疗效。
1992年至2008年间,确诊16例睾丸LCT患者。除1例肿瘤外,其余均可通过超声检测到。所有患者的甲胎蛋白和β-人绒毛膜促性腺激素水平均正常。8例患者接受了RO(手术时平均年龄42岁[27 - 61岁];肿瘤大小中位数12.9 mm[10 - 25 mm]),其余8例接受了TSS(手术时平均年龄34岁[18 - 49岁];肿瘤大小中位数8.6 mm[4 - 23 mm])。所有患者的分期(腹部计算机断层扫描和胸部X线或胸部计算机断层扫描)均为阴性。
RO术后中位随访时间为77个月(17 - 186个月),TSS术后为42个月(1 - 86个月)。RO术后患者无局部复发或转移。1例患者在同侧睾丸TSS术后29个月,从精索切除了异时性LCT。另1例患者在同侧TSS术后31个月因超声检查发现可疑病变而接受睾丸手术探查;组织病理学排除了肿瘤。
中期来看,对于肿瘤<25 mm的LCT患者,TSS是一种安全的手术方法。